Clinical Trials on Cutaneous Malignancy in Finland

Total 121 results

National Cancer Institute (NCI)

Active, not recruiting

Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery

Metastatic Cutaneous Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Recurrent Mucosal Melanoma | Metastatic Mucosal Melanoma | Non-Cutaneous Melanoma | Metastatic Non-Cutaneous Melanoma | Recurrent Non-Cutaneous...

United States, Canada, Ireland
Targovax Oy

Completed

ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers

Malignant Solid Tumour

Finland
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib for the Treatment of Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Recruiting

A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma

Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Melanoma of Unknown Primary | Stage IIIB Cutaneous Melanoma AJCC v7

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Helsinki University Central Hospital

Recruiting

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs (FINPROVE)

Solid Tumor | Advanced Cancer | Haematological Malignancy

Finland
Turku University Hospital

Completed

Rotating Frame Relaxation and Diffusion Weighted Imaging of Human Gliomas (RODIG)

Malignant Glioma | Low Grade Glioma

Finland
BioCryst Pharmaceuticals

Completed

Forodesine in the Treatment of Cutaneous T-Cell Lymphoma

Cutaneous T-cell Lymphoma (CTCL),

United States, Australia, Germany, Italy, Spain, France, Austria, Finland, Switzerland, United Kingdom
Amgen

Completed

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

Cutaneous Lupus Erythematosus

United States
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC... and other conditions

United States
MacroGenics

Active, not recruiting

MGD019 DART® Protein in Unresectable/Metastatic Cancer

Colorectal Cancer | Advanced Cancer | Prostate Cancer Metastatic | Cutaneous Melanoma | Solid Tumor, Adult | Squamous Cell Non Small Cell Lung Cancer

United States, Spain, Bulgaria, Poland, Ukraine
Chembrain LTD
University of Oulu; Jyväskylä Central Hospital; Apollo Hospital, New Delhi, India

Active, not recruiting

The Efficacy and Safety of Brain-targeting Immune Cells (EGFRvIII-CAR T Cells) in Treating Patients With Leptomeningeal Disease From Glioblastoma. Administering Patients EGFRvIII -CAR T Cells May Help to Recognize and Destroy Brain Tumor Cells in Patients (CARTREMENDOUS)

Glioblastoma | Glioblastoma Multiforme | Glioma, Malignant

Finland, India
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma

Locally Advanced Melanoma | Unresectable Melanoma | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8

United States
Hoffmann-La Roche

Completed

A Study of the Effect of Vemurafenib on the Pharmacokinetics of Phenprocoumon in Patients With BRAFV600 Mutation-Positive Metastatic Malignancy

Malignant Melanoma, Neoplasms

Belgium, Spain, Germany, Netherlands, Finland
Aalborg University Hospital
Turku University Hospital; Oslo University Hospital; Helsinki University Central... and other collaborators

Terminated

Stem Cell Factor (SCF) Priming of Haematopoietic Stem Cell Grafts in Malignant Lymphoma (SCF980266)

Malignant Lymphoma

Denmark, Sweden, Finland, Norway
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Advanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditions

United States
Novartis Pharmaceuticals

Completed

Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma

Italy, Spain, Belgium, Canada, Australia, Germany, Switzerland, United States, France, Argentina, Finland, Hungary
National Cancer Institute (NCI)

Completed

Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery

Stage IV Cutaneous Melanoma AJCC v6 and v7 | Recurrent Melanoma | Stage IIIC Cutaneous Melanoma AJCC v7 | Mucosal Melanoma | Iris Melanoma | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7 | Stage IV Uveal Melanoma AJCC v7 | Medium/Large Size Posterior Uveal Melanoma | Recurrent... and other conditions

United States
Celgene

Terminated

A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

Discoid Lupus

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects

Malignancy

United States
Kymera Therapeutics, Inc.

Recruiting

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

Solid Tumors | T-cell Prolymphocytic Leukemia (T-PLL) | Non Hodgkin Lymphoma (NHL) | Peripheral T-cell Lymphoma (PTCL) | Cutaneous T-Cell Lymphoma (CTCL) | Large Granular Lymphocytic Leukemia (LGL-L)

United States
National Cancer Institute (NCI)

Active, not recruiting

A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma

Clinical Stage III Cutaneous Melanoma AJCC v8 | Mucosal Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States
Numab Therapeutics AG

Recruiting

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Renal Cell Carcinoma | Mesothelioma, Malignant | Adenocarcinoma of Lung | Triple Negative Breast Cancer | Endometrial Cancer | Fallopian Tube Carcinoma | Peritoneal Carcinoma | Leiomyosarcoma | Liposarcoma | Ovarian Carcinoma | Adenocarcinoma of the Stomach | Melanoma, Malignant | Adenocarcinoma - Gastroesophageal...

United States
Precision BioSciences, Inc.

Recruiting

Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies

Hematologic Malignancy | CD19 Expressing Malignancies

United States
Bayer

Completed

First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin

Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma | Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma | Advanced Recurrent Serous Ovarian Cancer | Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)

United States, Sweden, Netherlands, United Kingdom, Finland
AUSL ROMAGNA
International Society of Geriatric Oncology; European Society of Surgical Oncology and other collaborators

Unknown

Geriatric Oncology Surgical Assessment and Functional rEcovery After Surgery (GOSAFE)

Elderly | Solid Malignancy

United States, Poland, Italy, Greece, Israel, Netherlands, Norway, Portugal, Spain, United Kingdom
Sigma-Tau Research, Inc.
Rhode Island Hospital

Completed

This is an Early Study to Investigate the Effect of Gimatecan® in Adults With Malignant Glioma.

Malignant Glioma

United States
Adam Olszewski

Active, not recruiting

Removing Transfusion Dependence as a Barrier to Hospice Enrollment (BRUOG-407)

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Leukemia | Hematologic Malignancy | Myeloma

United States
Novartis Pharmaceuticals

Completed

A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene

Unresectable or Metastatic Malignant Gastrointestinal Stromal Tumor (GIST)

United States, Finland, Australia
Thomas Zilli

Active, not recruiting

Hypofractionated Radiation Therapy in Prostate Cancer

Malignant Neoplasm of Prostate | Local Disease

Netherlands, Israel, Switzerland, Spain, Belgium, Finland, Portugal, Turkey
National Cancer Institute (NCI)

Suspended

Testing Pembrolizumab Versus Observation in Patients With Merkel Cell Carcinoma After Surgery, STAMP Trial

Pathologic Stage I Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage II Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8

United States
European Organisation for Research and Treatment...

Terminated

Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides

Lymphoma

Spain, Finland, France, Germany, Switzerland, Belgium, Netherlands, Italy, Israel, Denmark, Hungary, United Kingdom, Austria
Purdue Pharma LP

Terminated

Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain

Chronic Non-Malignant Pain

United States
Sanofi

Completed

Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Hematological Malignancy

Greece, Spain, Peru, Israel, United States, Argentina, Belgium, Brazil, Chile, Finland, France, Italy, Mexico, Russian Federation, Turkey, Ukraine, United Kingdom
University of Aarhus

Active, not recruiting

Phase 1/2 Study of the Combination of Pixantrone, Etoposide, Bendamustine and, in CD20 Positive Tumors, Rituximab in Patients With Relapsed Aggressive Non-Hodgkin Lymphomas of B- or T-cell Phenotype - the P[R]EBEN Study

Malignant Lymphoma

Netherlands, Norway, Denmark, Finland, Sweden
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Reproductive Health Program in Patients With Cancer (EROS)

Malignant Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

Biphasic Mesothelioma | Epithelioid Mesothelioma | Stage III Pleural Malignant Mesothelioma AJCC v7 | Stage I Pleural Malignant Mesothelioma AJCC v7 | Stage IA Pleural Malignant Mesothelioma AJCC v7 | Stage IB Pleural Malignant Mesothelioma AJCC v7 | Stage II Pleural Malignant Mesothelioma AJCC...

United States
Brown University
Actuate Therapeutics Inc.

Withdrawn

A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas

Sarcoma | Soft Tissue Sarcoma | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Metastatic Sarcoma | Myxofibrosarcoma | Spindle Cell Sarcoma

United States
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

Malignant Solid Neoplasm

United States, Puerto Rico
Oblato, Inc.

Active, not recruiting

Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma

Recurrent Malignant Glioma | Brain Glioblastoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Neuropsychological and Behavioral Testing in Younger Patients With Cancer

Childhood Malignant Neoplasm

United States, Canada, Puerto Rico, Australia, New Zealand
Brown University
Actuate Therapeutics Inc.

Withdrawn

Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma

Soft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma of Bone | Leiomyosarcoma | High Grade Sarcoma | Liposarcoma | Rhabdomyosarcoma | Angiosarcoma | Bone Sarcoma | Synovial Sarcoma | Undifferentiated Pleomorphic Sarcoma | Myxofibrosarcoma | Spindle Cell Sarcoma

United States
Aadi Bioscience, Inc.

Active, not recruiting

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

Malignant Solid Neoplasm | Neoplasms | Cancer | Neoplasm Metastasis | Solid Tumor | Metastatic Cancer | Metastasis | Advanced Solid Tumor | Metastatic Solid Tumor | Advanced Cancer | Tumor | Malignant Neoplasm | Malignant Tumor | Tumors | Cancer Metastatic | Tumor, Solid | Malignant Solid Tumor | TSC | TSC1 | TSC2 | Metastatic Neoplasm

United States, Korea, Republic of, Puerto Rico
National Cancer Institute (NCI)

Recruiting

National Cancer Institute "Cancer Moonshot Biobank"

Malignant Solid Neoplasm | Acute Myeloid Leukemia | Multiple Myeloma | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IV Breast Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer... and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI); MedStar Georgetown University Hospital

Active, not recruiting

Mobile Health and Social Media Physical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors, the StepByStep Study

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm

United States, Canada
Hoffmann-La Roche

Completed

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

Malignant Melanoma

United States, Australia
MedtronicNeuro

Completed

Embrace TDD: Post-Market Study to Evaluate Intrathecal Morphine as an Alternative to Systemic Opioids for Chronic Pain

Chronic Pain | Pain, Back | Chronic Non-malignant Pain | Pain, Leg

United States

Clinical Trials on Cutaneous Malignancy in Finland

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations